Sign in
Taking people in South AfricaNo phase

Tests nurse-led care for drug-resistant tuberculosis in primary care clinics

Compares nurse-led treatment at clinics with doctor-led care at hospitals for adults with drug-resistant tuberculosis.

Key facts

Who runs it
Johns Hopkins University
Where
East London, Pietermaritzburg, Port Elizabeth, and Port Shepstone, South AfricaSee the 5 sites
Trial code
Registry title
Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment
Status
Recruiting
People taking part
2,944 people, planned
Started
4 Sept 2023
Expected to end
31 Dec 2030
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Nurse-Led Treatment in Primary Care
Record updated
26 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a new diagnosis of rifampicin-resistant TB (RR-TB), with or without HIV, who can be treated as outpatients.

Age
18 years and older
Sex
All sexes
Disease stage
New RR-TB diagnosis, well enough to start treatment as an outpatient in primary care

Main reasons for not taking part

  • Needs to be admitted to hospital (for example severe weakness, confusion, severe shortness of breath)
  • Low hemoglobin (below 8mg/dL) or liver disease (ALT above 120 U/L)
  • Prolonged QTc above 470ms, confirmed by 2 or more ECGs
  • Fast heartrate (above 140), confirmed after 5 minutes of rest
  • Pregnancy

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Cluster Inclusion Criteria:
  • Primary Care Clinics (PCCs) (i.e., clusters) are eligible if they meet the following:
  • within one of the selected hospital treatment catchment areas in Kwazulu-Natal, Gauteng and Eastern Cape Provinces
  • willingness of provincial TB program managers and hospital leadership to participate
  • willingness of PCC nurse manager to participate
  • diagnosis of 10 or more RR-TB patients per year; and
  • have access to necessary labs, X-ray and electrocardiogram (ECG) equipment; Participant Inclusion Criteria:; Adult participants aged 18 years of age and older, regardless of HIV status, who have a new RR-TB diagnosis, deemed willing and able to provide informed consent in one of the four most common SA languages [Zulu, Xhosa, Afrikaans, and English] will be eligible; Participant Exclusion Criteria:
  • any clinical presentation requiring hospital admission or, in other words, the participant is not a candidate for outpatient primary care initiation (e.g., severe weakness, confusion, severe mental illness, symptomatic low blood pressure, severe shortness of breath, and temp >39.0)
  • Hemoglobin < 8mg/dL (from National Health Laboratory Service (NHLS) or point of care)) or liver disease (ALT > 120 U/L)
  • prolonged QTc>470ms, confirmed by 2 or more ecg
  • rapid heartrate, tachycardia (HR >140); confirmed after 5 minutes of rest
  • pregnancy
  • evidence of extrapulmonary disease
  • enrolled in another clinical trial that changes BPaL-L regimen, duration or symptom management process

This trial is currently available in South Africa.

  • King Dinuzulu TB HospitalEast London, South AfricaContact: Jason Farley, PhDTaking people
  • Nkquebela TB HospitalEast London, South AfricaContact: Jason Farley, PhDTaking people
  • Doris Goodwin HospitalPietermaritzburg, South AfricaContact: Jason Farley, PhDTaking people
  • Jose Pearson HospitalPort Elizabeth, South AfricaContact: Jason Farley, PhDTaking people
  • Murchison HospitalPort Shepstone, South AfricaContact: Jason Farley, PhDTaking people

About the trial

What the trial wants to find out

The goal of the BringBPaL2Me Trial, a multi-principal investigator, multi-site, cluster randomized, non-inferiority trial is to compare nurse-led RR-TB treatment in primary care clinics to standard of care physician-led RR-TB treatment at district hospitals in the provinces of KwaZulu-Natal, Gauteng, and Eastern Cape.

Read full original descriptionShow less

The main aim is to conduct a 5-year, analyst and clinical safety review committee blinded, multi-site, cluster randomized trial to evaluate 1) treatment outcome; 2) safety; 3) patient associated catastrophic costs with the following hypotheses:

1. Outpatient nurse-led treatment in PCCs will be non-inferior to outpatient physician-led treatment at hospital-based outpatient sites among RR-TB patients, regardless of HIV co-infection, as determined by a successful treatment outcome [H1]. 2. The proportion of SAEs identified will not significantly differ by blinded, independent review [H2]. 3. Patient associated catastrophic costs (i.e., costs 20% or more of household income) will be lower in nurse-led treatment [H3].

The 2 groups in the trial

  • Nurse-Led Treatment in Primary CareTreatment being tested

    At a primary care clinic intervention site, a nurse will be available once or twice weekly. The days/times will be dependent on clinic volume (i.e., cluster size), with scheduled rotations between PCCs. This rotation between PCC sites will mimic the physician's responsibilities/availability at a district hospital and creates parity between the trial arms. In this trial, we will have nurses dedicated to the management of RR-TB treatment, yet the volume at each site will not require the presence of a full-time nurse.

  • Physician-Led Treatment Hospital BasedNo study treatment, for comparison

    Representing standard of care, primary care clinics will refer to hospital-based, physician-led care who will provide outpatient treatment. The typical clinical operations involve initiation of new patients once or twice weekly and PCCs are required to schedule a clinic day/time for the patient prior to referral (generally \< 72 hours from the time of referral). All individuals receiving care at this site will receive care at the district RR-TB treatment program for the catchment area. For HIV co-infected persons, their HIV treatment is also transferred to the RR-TB physician with details about the HIV treatment communicated in the transfer of care letter. Physicians often cover multiple clinics and routinely take on call sessions on the weekend, due to staffing limitations, thus preventing their sole focus on the RR-TB program and limiting the number of days the RR-TB clinic offers new patient visits and, in most cases, days for follow-up visits.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment in Primary Care to Physician-Led, Hospital-Based Outpatient RR-TB Treatment: A Cluster Randomized, Non-Inferiority Trial
Plain-language title
Tests nurse-led care for drug-resistant tuberculosis in primary care clinicsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 October 2026